NephJC Shorts
Nephrology produces far more new studies each week than NephJC can realistically cover in its twice‑monthly full reviews. That’s why we’re introducing NephJC Short- quick, sharp summaries of notable papers that caught the editorial team’s attention. Suggestions welcome, and feedback too.
🩳Read more on the blog post describing this initiative.
Upcoming NephJC Shorts
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial (Neuen BL et al, JAMA, 2026)
Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY) (Neuen BL, Lancet, 2026)Nondialyzable versus Dialyzable Beta-Blockers in Hemodialysis (Etemadi A et al, JASN, 2026)
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial (Heerspink HJL et al, Lancet, 2026)
Vasopressors or Fluids in Early Septic Shock (ARISE Fluids investigators, NEJM, 2026)
Increasing Plasma Sodium with Tolvaptan Under Regulated Water Intake (Sweis NW et al, Am J Physiol Renal Physiol. 2026)
Does Dual BAFF/APRIL Blockade with Telitacicept Reduce Proteinuria in Persistent Proteinuric IgA Nephropathy?
A post hoc analysis from TESTINg tries to answer this question
Is measured GFR more accurate than eGFR for forecasting adverse outcomes?
Can polymyxin B hemadsorption truly shift the fate of septic shock, or is the outcome already written?
In type 1 diabetes is finerenone helpful to reduce proteinuria?
Water, water everywhere. Can a wink, a nudge and a push increase water intake to decrease kidney stone formation?
The NephJC shorts on cost-efficiency of low-protein diets and ketoanalogues as a distraction from CKD-relevant therapies in the 21st century… wait, only if the comparator wouldn’t be dialysis.
The NephJC shorts on APPEAR-G3C randomized controlled trial: iptacopan in C3GN
We break down the latest salvo from Zarbock et al on a supposedly wonderful ‘bundle’
The NephJC shorts version of the Hypertension medication step-down in a nursing home population from NEJM
NephJC short on an empagliflozin meta-analysis
A NephJC Shorts discussion of the long term data on kidney failure in FSGS and MCD
Another try: will spironolactone bring better outcomes in maintanance dialysis?
the NephJC shorts version of the KARDIA1
